TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI

Bookmark and Share
Published: 15 Apr 2019
Views: 921
Rating:
Save
Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA

Prof Lecia Sequist speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the TATTON study looking at osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on fist/second generation EGFR-TKI or third generation EGFR-TKI.

She reports that patients that were biomarker selected due to their MET driven resistance are responding well to the EGFR plus MET combination.

Prof Sequist informs that patients who previously received a first/second generation EGFR inhibitor (and are T790-negative and MET-positive) had a response rate of 52% compared with 25% for patients who received a third generation drug.

Read more about this research here.